Department of Obstetrics and Gynecology, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Taijiang District, Fuzhou, 350000 Fujian, China.
Department of Gynecology, First Affiliated Hospital of Kunming Medical University, No. 295, Xichang Road, Wuhua District, Kunming, Yunnan 650032, China.
Biomed Res Int. 2022 Jun 6;2022:4557346. doi: 10.1155/2022/4557346. eCollection 2022.
The time interval rules and survival outcomes of individuals with synchronous and metachronous breast cancer (BC) and ovarian cancer (OC) were examined in this retrospective population-based investigation.
The National Cancer Institute's Surveillance, Epidemiology, and End Results database was used to create a cohort of people diagnosed with BC and OC between 1973 and 2015. Patients were separated into three groups: those with main BC followed by primary OC (group 1), those with synchronous primary breast and ovarian cancer (group 2), and those with OC prior to BC (group 3). The Kaplan-Meier technique was used to assess overall survival (OS) and cancer-specific survival (CSS).
A total of 4,975 patients were identified: 2,929 patients in group 1, 680 patients in group 2, and 1,366 patients in group 3. The average duration between these tumors was 60 months (range 0-499). Approximately 50% of second primary cancer cases occurred during the first 60 months of the first primary cancer diagnosis, and more than 70% occurred within the first 120 months. The median survival time for 4,975 individuals was 140 months. Group 2 had the smallest median OS (35 months), whereas group 3 had the longest (45 months) (239 months).
The majority of second primary cancer cases occurred during the first 120 months following the diagnosis of the first original malignancy. Individuals who had primary OC prior to BC had better prognoses, whereas patients who had synchronous BC and OC had worse prognoses.
本回顾性基于人群的研究旨在探讨同时性和异时性乳腺癌（BC）和卵巢癌（OC）个体的时间间隔规则和生存结局。
利用美国国家癌症研究所的监测、流行病学和最终结果数据库，创建了一组 1973 年至 2015 年间诊断为 BC 和 OC 的患者队列。患者被分为三组：主要 BC 后发生原发性 OC（组 1）、同时性原发性乳腺和卵巢癌（组 2）以及 BC 前发生 OC（组 3）。采用 Kaplan-Meier 技术评估总生存期（OS）和癌症特异性生存期（CSS）。
共确定了 4975 名患者：组 1 2929 名，组 2 680 名，组 3 1366 名。这些肿瘤之间的平均间隔时间为 60 个月（范围 0-499）。约 50%的第二原发癌病例发生在首次原发性癌症诊断后的前 60 个月内，超过 70%发生在首次诊断后的 120 个月内。4975 名个体的中位生存时间为 140 个月。组 2 的中位 OS 最短（35 个月），而组 3 最长（45 个月）（239 个月）。
大多数第二原发癌病例发生在首次原发性恶性肿瘤诊断后的前 120 个月内。原发性 OC 先于 BC 的患者预后较好，而同时性 BC 和 OC 的患者预后较差。
